Clinical trials: Lamivudine
Lactating Women on Select DOI, Breastmilk Fed Infants of Mothers on Select DOI
Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana
The purpose of this study is to characterize the pharmacokinetics (PK) of understudied drugs administered to lactating women, receiving antiretroviral drugs per SOC as prescribed by their healthcare provider, and their…
- Conditions
- Lactating Women on Select DOI, Breastmilk Fed Infants of Mothers on Select DOI, HIV Infections
- Trial name
- BMS02 (NCT04862975)
- Testing
- Dolutegravir, Lamivudine, Emtricitabine
- Where
- 4 sites in South Africa
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Duke University
HIV-1-infection
A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy
This is an open label, randomised, phase 3, two-arm study conducted over 96 weeks. The study includes a screening period day - 60 to -1, enrolment visit day 0, and a 96-week treatment follow-up period.
- Trial name
- Opti-DOR (NCT05924438)
- Testing
- Delstrigo, KOCITAF
- Where
- South Africa
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Professor Francois Venter
HIV Prevention
Demonstration Project on the Feasibility to Implement PrEP in MSM and TG Women
The purpose of the study is to evaluating the acceptability, use and adherence of a pre-exposure prophylaxis (PrEP) program using the co-formulation tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF/FTC) administered…
- Trial name
- NCT03043326
- Testing
- Tenofovir Disoproxil Fumarate and Emtricitabine
- Where
- 5 sites in Peru
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Asociación Civil Impacta Salud y Educación, Peru
Non-Hodgkin's Lymphoma
A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen
AIMS OF THE STUDY (STUDY OBJECTIVES) 1. To test the effect of daily lamivudine (100 mg) in reducing the risk of HBV reactivation and hepatitis development in HBsAg (+) NHL patients. 2.
- Trial name
- NCT00201318
- Testing
- Cyclophosphamide Doxorubicin Vincristine Lamivudine
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Healthy
A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)
The goal of this study is to learn what happens to the medication islatravir (ISL), in a healthy person's body over time--called a pharmacokinetic (PK) study.
- Trial name
- NCT06811246
- Testing
- Islatravir (ISL), Lamivudine (3TC)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV
Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics
This study evaluated the blood and blood cell concentrations of zidovudine and lamivudine in men versus women and in those with versus without HIV infection.
- Trial name
- NCT01386970
- Testing
- zidovudine 300mg and lamivudine 150mg as Combivir
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
HIV Infections
To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers
This is a 2-part, single-dose, open label, randomized 3-way cross-over study to compare BA of pediatric study drugs TRIUMEQ and (DTG/3TC) in healthy volunteers under fasted conditions. Study will be conducted in 2-parts.
- Trial name
- NCT03441984
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infection, Infection, Human Immunodeficiency Virus
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and…
- Trial name
- NCT00085943
- Testing
- LEXIVA (GW433908), Ritonavir, KALETRA
- Where
- 119 sites in United States, Austria and 12 more
- Volunteers
- 866 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ebola, HIV/AIDS
Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy
Ebola and HIV are found predominately in the same regions of the world and countries in sub-Saharan Africa are most affected by both diseases. For Ebola, no approved therapies exist.
- Trial name
- RemTLAR (NCT04385719)
- Testing
- Remdesivir
- Where
- Uganda
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Makerere University
HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
This is a prospective, non-randomised, 48 week study of the effect of protease inhibitor (PI) containing and non-PI containing antiretroviral regimens on the expression of adipocyte specific genes, protein levels and cellular…
- Trial name
- NCT00192660
- Testing
- Lamivudine, Stavudine, Didanosine
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
HIV Infections
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
The purpose of this study is to find out whether these powerful combinations of anti-HIV drugs are safe and effective for use in patients in the early stages of HIV infection and to find out how patients' immune systems react to…
- Trial name
- NCT00001119
- Testing
- Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine
- Where
- 12 sites in United States, Australia
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HBV Carrier
Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration
Hepatocellular carcinoma (HCC) is a very severe disease in Taiwan caused 7,000 deaths per year, and majorly about 70% is caused by the chronic hepatitis B virus infection.
- Trial name
- NCT02953600
- Testing
- Standard Dose Spirulina Platensis, Zero Spirulina Platensis, Double Dose Spirulina Platensis
- Where
- Taiwan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
HIV Infections
Preventing Sexual Transmission of HIV With Anti-HIV Drugs
This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not.
- Trial name
- NCT00074581
- Testing
- Atazanavir, Didanosine, Efavirenz
- Where
- 17 sites in United States, Botswana and 7 more
- Volunteers
- 3,526 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Disorder Related to Transplantation, Virus Diseases
Replacement of Lamivudine by Telbivudine to Improve Renal Function
Nephrotoxicity is one of the adverse effects of lamivudine and dosage of lamivudine has to be reduced if patients' renal function is insufficiency. Telbivudine may improve glomerular filtration rate.
- Conditions
- Disorder Related to Transplantation, Virus Diseases, Injury Due to Exposure to External Cause
- Trial name
- NCT02447705
- Testing
- telbivudine
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Infection, Human Immunodeficiency Virus
Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine
This study aims to compare the bioequivalence of two experimental fixed dose combination (FDC) tablets versus single entity products of dolutegravir (DTG) and lamivudine (3TC) in healthy adult subjects.
- Trial name
- NCT03078556
- Testing
- Dolutegravir, Lamivudine, Dolutegravir + Lamivudine FDC Formulation 1
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
Lamivudine (3TC) is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and children.
- Trial name
- NCT02634073
- Testing
- Lamivudine, Sorbitol
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infection
Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa
This is a funded implementation study designed to evaluate the efficacy of recruiting and retaining high-risk individuals on pre-exposure prophylaxis (PrEP) within multiple private pharmacies (and online platforms in South Africa)
- Trial name
- PPREPP-SA (NCT07006246)
- Testing
- Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC)
- Where
- South Africa
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- Professor Francois Venter
Healthy Subjects, Infection, Human Immunodeficiency Virus
Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets
Dolutegravir (DTG, GSK1349572) is a next-generation integrase inhibitor (INI) currently in phase 3 clinical trials for human immunodeficiency virus (HIV).
- Trial name
- NCT01366547
- Testing
- Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations
Dolutegravir (DTG) and lamivudine (3TC) are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
- Trial name
- NCT02738931
- Testing
- Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects
The abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) 600 milligrams (mg)/50 mg/300 mg fixed-dose combination (FDC) tablet is currently approved in the United States (US) and Europe.
- Trial name
- NCT02539576
- Testing
- ABC/DTG/3TC FDC tablet
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare